QuantHealth Introduces AI-Powered Solution for Scaling Clinical Trials

TL;DR:

  • Tel Aviv-based startup, QuantHealth, unveils Katina, an AI-driven platform for clinical trial design.
  • Katina can simulate numerous trial protocol combinations, optimizing patient groups, treatment parameters, and endpoints.
  • The platform leverages real-world data from 350 million patients, yielding an impressive 86% endpoint prediction accuracy.
  • QuantHealth secured $15 million in series A funding for expansion and product development, bringing their total external funding to $20 million.

Main AI News:

In a significant move within the healthcare innovation landscape, Tel Aviv-based startup QuantHealth has unveiled its cutting-edge platform, Katina. Designed to harness the power of artificial intelligence, Katina revolutionizes clinical study design by offering a seamless workflow guided by AI, capable of simulating an impressive array of potential trial protocol combinations.

This groundbreaking platform isn’t just about numbers; it delves deep into patient groups, treatment parameters, and diverse endpoints, all of which play pivotal roles in the operational and commercial aspects of a clinical trial. QuantHealth’s latest endeavor is underpinned by AI technology fueled by real-world data from an astounding 350 million patients, bolstered by comprehensive biomedical knowledge graphs and valuable trial data. Impressively, the startup boasts an astonishing endpoint prediction accuracy rate of 86% for investigational therapies.

QuantHealth’s commitment to innovation and excellence is further exemplified by its recent achievement of securing $15 million in series A funding back in late August. The infusion of capital was strategically earmarked for commercial expansion, product development, and the ambitious goal of extending its platform’s reach beyond clinical trials and into the realm of regulatory support. With the latest financing round, QuantHealth has successfully raised a cumulative total of $20 million in external funding.

Conclusion:

QuantHealth’s Katina represents a game-changing development in the healthcare market. By harnessing AI and real-world data, it promises to enhance the efficiency and accuracy of clinical trials. This innovation positions QuantHealth as a leading player in the industry, with the potential to reshape how healthcare research is conducted and accelerate the development of new therapies.

Source